Arbutus Biopharma Corp (ABUS) Form 10-Q — Aug 12, 2026
Arbutus Biopharma's Q2 2026 10-Q shows six-month net income of $164.6 million ($0.84 per share) driven by $178.4 million of license revenue from its share of the $950.0 million Moderna LNP patent settlement paid July 8, 2026. The second quarter on a standalone basis was a $5.1 million net loss on just $1.0 million of total revenue. The balance sheet was transformed: $92.6 million of cash, equivalents and marketable securities with no debt, stockholders' equity of $258.7 million, and the $179.4 million Genevant receivable collected after quarter-end.
Key figures
- Eps
- 0.84
- Revenue
- 180140000
- Net Income
- 164552000
- Total Debt
- 0
- Total Assets
- 274025000
- Cash Position
- $92.6 million (cash and equivalents of $19.2 million plus marketable securities of $73.5 million)
- Shares Outstanding
- 197634118
- Q2 2026 revenue
- 1014000
- Genevant ownership
- approximately 16% (carrying value zero)
- Six month 2025 revenue
- 12503000
- Genevant rsv termination fee
- 1000000
- Six month operating cash burn
- 14128000
- Enantigen max sales milestones
- 102500000
- Omers royalties earned to date
- 26900000
- Receivable from genevant license
- 179373000
- Stockholders equity june 30 2026
- 258733000
- Contingent consideration liability
- 8800000
- Contingent settlement payment up to
- 1300000000
- Moderna noncontingent settlement total
- 950000000
- Arbutus share of settlement received july 8 2026
- 178400000
Price after filing
Close on the filing date to close N calendar days later (from $4.59). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.